This article is more than 5 years old. Information may no longer be current.

Study results show Boston Scientific SCS system offers LBP relief

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Boston Scientific announced in a press release that according to data presented at the World Institute of Pain Congress, the company’s Precision Spectra Spinal Cord Stimulator System can provide sustained and significant relief of low back pain 6 months after implantation.

“Boston Scientific specifically developed the Precision Spectra System to achieve better therapy outcomes,” Maulik Nanavaty, president, Neuromodulation, Boston Scientific, stated in the press release. “These 6-month results demonstrate our dedication to improving the lives of patients with chronic pain through meaningful innovation. We look forward to the long-term outcomes of this ongoing clinical study.”

Precision Spectra is the first spinal cord stimulation (SCS) system designed to improve pain relief using the Illumina 3D Software, a 3-D anatomy-driven computer model. Because it takes into account the conductivity of 3-D anatomical structures and physician placement of the SCS leads, the Illumina 3D software is designed for simple point-and-click pain targeting, as noted in the press release.

The retrospective study presented at the meeting included 213 patients with chronic pain treated at 13 centers with the Precision Spectra SCS System. In patients with 6-month follow-up average pain reduction on a 10-point scale changed from 7.15 points at baseline to 2.93 points at 6 months after implantation.